Under a new licensing pact, Synaffix will grant Boehringer Ingelheim access to its bespoke ADC technologies for an "agreed but undisclosed number of targets." The first target was decided by the ...

Learn how turkey producers in the U.S. will soon be able to vaccinate their birds to prevent the highly contagious disease.

The collaboration with Oxford BioTherapeutics complements Boehringer Ingelheim’s development of next-generation life-changing cancer immunotherapies with the identification of unique and ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials. The phase 3 program missed both primary ...

AMSTERDAM, BASEL, Switzerland and INGELHEIM, Germany, Jan. 9, 2025 /PRNewswire/ -- Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were ...